Research brief: Obesity affects asthma medication

Obesity is associated with more severe asthma, and reduced response to treatment, according to a meta-analysis of placebo-controlled clinical trials of beclomethasone and montelukast.

Obesity is associated with more severe asthma, and reduced response to treatment, according to a meta-analysis of placebo-controlled clinical trials of beclomethasone and montelukast.

The US researchers found that obese patients in both placebo groups had worse asthma control but obesity affected the efficacy of the two treatments in different ways. The effectiveness of beclomethasone declined with increasing BMI, but there was no impact of BMI on the effectiveness of montelukast treatment (http://erj.ersjournals.com).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus